Empagliflozin in heart failure with preserved ejection fraction with and without atrial fibrillation

Atrial fibrillation/flutter (AF) is common in heart failure (HF) with preserved left ventricular ejection fraction (LVEF) and associated with worse outcomes. Empagliflozin reduces cardiovascular death or HF hospitalizations and slows estimated glomerular filtration rate (eGFR) decline in patients with HF and LVEF >40%. We aimed to assess the efficacy and safety of empagliflozin in improving outcomes in patients with HF and LVEF >40% with and without AF.

[1]  I. V. Van Gelder,et al.  Atrial disease and heart failure: the common soil hypothesis proposed by the Heart Failure Association of the European Society of Cardiology. , 2021, European heart journal.

[2]  Akshay S. Desai,et al.  Dapagliflozin and atrial fibrillation in heart failure with reduced ejection fraction: insights from DAPA‐HF , 2021, European journal of heart failure.

[3]  A. Kjær,et al.  Effect of empagliflozin on myocardial structure and function in patients with type 2 diabetes at high cardiovascular risk: the SIMPLE randomized clinical trial , 2021, The International Journal of Cardiovascular Imaging.

[4]  P. Ponikowski,et al.  Empagliflozin in Heart Failure with a Preserved Ejection Fraction. , 2021, The New England journal of medicine.

[5]  H. Tse,et al.  Sodium-glucose cotransporter 2 inhibitors (SGLT2i) and cardiac arrhythmias: a systematic review and meta-analysis , 2021, Cardiovascular Diabetology.

[6]  Ruicong Xue,et al.  Usefulness of CHADS2, R2CHADS2, and CHA2DS2‐VASc scores for predicting incident atrial fibrillation in heart failure with preserved ejection fraction patients , 2021, ESC heart failure.

[7]  L. Køber,et al.  Associations of Empagliflozin With Left Ventricular Volumes, Mass, and Function in Patients With Heart Failure and Reduced Ejection Fraction: A Substudy of the Empire HF Randomized Clinical Trial. , 2021, JAMA cardiology.

[8]  B. Yeap,et al.  Empagliflozin and left ventricular diastolic function following an acute coronary syndrome in patients with type 2 diabetes , 2020, The International Journal of Cardiovascular Imaging.

[9]  D. Choi,et al.  Impact of atrial fibrillation in patients with heart failure and reduced, mid-range or preserved ejection fraction , 2020, Heart.

[10]  L. Lund,et al.  Interdependence of Atrial Fibrillation and Heart Failure With a Preserved Ejection Fraction Reflects a Common Underlying Atrial and Ventricular Myopathy , 2020, Circulation.

[11]  B. Zinman,et al.  Efficacy of empagliflozin on heart failure and renal outcomes in patients with atrial fibrillation: data from the EMPA‐REG OUTCOME trial , 2019, European journal of heart failure.

[12]  G. Filippatos,et al.  Prognostic implications of atrial fibrillation in heart failure with reduced, mid-range, and preserved ejection fraction: a report from 14 964 patients in the European Society of Cardiology Heart Failure Long-Term Registry , 2018, European heart journal.

[13]  L. Lund,et al.  Atrial Fibrillation in Heart Failure With Preserved, Mid-Range, and Reduced Ejection Fraction. , 2017, JACC. Heart failure.

[14]  A. Rigby,et al.  Heart Rate and Rhythm and the Benefit of Beta-Blockers in Patients With Heart Failure. , 2017, Journal of the American College of Cardiology.

[15]  G. Filippatos,et al.  How to Use Beta-Blockers in Heart Failure With Reduced Ejection Fraction and Atrial Fibrillation. , 2017, Journal of the American College of Cardiology.

[16]  I. V. Van Gelder,et al.  Atrial Fibrillation in Heart Failure With Preserved Ejection Fraction: Association With Exercise Capacity, Left Ventricular Filling Pressures, Natriuretic Peptides, and Left Atrial Volume. , 2017, JACC. Heart failure.

[17]  V. Roger,et al.  Temporal Relationship and Prognostic Significance of Atrial Fibrillation in Heart Failure Patients With Preserved Ejection Fraction: A Community-Based Study , 2013, Circulation.